通过半理性工程来改善GenB3和GenB4在 جنت米辛二氧化二氧化生物合成中的活性
Hang Zhai1, Lihua Yang1, Qi Ye1
1School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, No.103 Wenhua Road, Shenyang, Liaoning, China.
Microbial cell factories
|February 27, 2025
概括
研究人员开发了改进的合成半合成氨基糖化物 (AG) 抗生素的方法,增强了它们对细菌感染的活性. 这项工作通过改进化学途径和创造更强效的候选药物来简化AG抗生素的开发.
科学领域:
- 药用化学 医学化学
- 抗生素合成 抗生素合成
- 分子生物学分子生物学
背景情况:
- 氨基糖化物 (AG) 抗生素对于治疗细菌感染至关重要.
- 目前的半合成AG生产涉及低效,耗时的化学过程.
- 这些低效率阻碍了新型AG的发现.
研究的目的:
- 开发一种更高效和温和的合成C6'-修饰AG类似物.
- 通过半理性设计,增强现有AG的抗菌活性.
- 为合成各种AG组件提供基础.
主要方法:
- 利用工程酶GenB3和GenB4进行AG合成.
- 采用了一种半理性的策略来创造酶突变 (GenB3M1,GenB3M2,GenB4M1,GenB4M2>).
- 在工程菌株中验证了突变疗效,并使用了分子动态模拟.
主要成果:
- 通过使用GenB3和GenB4合成了西索米辛,奥克索 - 维尔达米辛,奥克索 - 珍塔米辛C1a和奥克索 - 珍塔米辛C2a.
- 基因B3突变体对特定基质的活性高出1.34-1.74倍.
- 基因B4突变体对西索米辛和维达米辛C2a具有1.51-1.34倍的活性.
- 在工程菌株中证实了突变疗效;模拟揭示了作用机制.
结论:
- 建立了一种温和而高效的方法来合成C6'-改性AG类似物.
- 开发的酶变体是AG药物发现的宝贵工具.
- 为增强M. echinospora的脱氧化过程提供了一个参考,用于新型AG合成.
更多相关视频
06:24Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
10.0K
08:31Anaerobic Protein Purification and Kinetic Analysis via Oxygen Electrode for Studying DesB Dioxygenase Activity and Inhibition
Published on: October 3, 2018
8.4K
相关概念视频
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
